The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors

Biochemistry

Volumn 47, Issue 51, 2008, Pages 13481-13488

  Langley, David R ^a   Samanta, Himadri K ^a   Lin, Zeyu ^a   Walker, Michael A ^a   Krystal, Mark R ^a   Dicker, Ira B ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITES; BINDING MODELS; BOUND INHIBITORS; BOUND STATES; COMPETITIVE INHIBITORS; DIRECT INTERACTIONS; INHIBITOR BINDINGS; INHIBITOR DISSOCIATIONS; INTEGRASE; KINETIC EXPERIMENTS; LTR CONTROLS; MAGNESIUM ATOMS; SYSTEMATIC CHANGES;

BINDING ENERGY; DISSOCIATION; MAGNESIUM; PORT TERMINALS; SUGAR (SUCROSE); SUGARS;

BINDING SITES;

ADENOSINE; DEOXYRIBOSE; INTEGRASE; INTEGRASE INHIBITOR;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVE SITE; KINETICS; MODEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE;

3' UNTRANSLATED REGIONS; ADENOSINE; BINDING, COMPETITIVE; CATALYTIC DOMAIN; CHEMISTRY, PHARMACEUTICAL; HIV; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV LONG TERMINAL REPEAT; KINETICS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; TEMPERATURE;

EID: 58149154667     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi801372d     Document Type: Article

References (47)

1. LaFemina, R. L., Schneider, C. L., Robbins, H. L., Callahan, P. L., LeGrow, K., Roth, E., Schlief, W. A., and Emini, E. A. (1992) Requirement of Active Human Immunodeficiency Virus Type 1 Integrase Enzyme for Productive Infection of Human T-Lymphoi Cells. J. Virol 66, 7414-7419.
2. Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., and Miller, M. D. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646-650.
3. Assante-Appiah, E., Skalka, A. M. (1999) HIV-1 integrase: structural organization, conformational changes, and catalysis, in Advances in Virus Research, pp 351-369, Academic Press
4. Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., Cole, J. L., and Hazuda, D. J. (2000) HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U.S.A. 97, 11244-11249.
5. Pommier, Y., Johnson, A. A., and Marchand, C. (2005) Integrase inhibitors to treat HIV/Aids. Nat. Rev. Drug Discovery 4, 236-248.
6. Cooper, D. A., Gatell, J., Rockstroh, J., Katlama, C., Yeni, P., Lazzarin, A., Chen, J., Isaacs, R., Teppler, H., Nguyen, B.-Y., and Group, B.-S. (2007) Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safey of raltegravir (MK-0518), a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, p 105LB, Denver, CO, Feb 5-8, 2006.
7. Kawaguchi, I., Ishikawa, T., Ishibashi, M., Irie, S., Kakee, A. (2006) Safety and Pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers, presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI), Feb 5-8, Denver, CO, Poster #580.
8. Engelman, A., Mizuuchi, K., and Craigie, R. (1991) HIV-1 DNA Integration: Mechanism of Viral DNA Cleavage and DNA Strand Transfer. Cell 67, 1211-1221.
9. Bushman, F. D., Fujiwara, T., and Craigie, R. (1990) Retroviral DNA Integration Directed by HIV Integration Protein in vitro. Science 249, 1555-1557.
10. Ellison, V., and Brown, P. O. (1994) A Stable Complex Between Integrase and Viral DNA ends Mediates Human Immunodeficiency Virus Integration in vitro. Proc. Natl. Acad. Sci. U.S.A. 91, 7316-7320.
11. Hazuda, D. J., Young, S. D., Guare, J. P., Anthony, N. J., Gomez, R. P., Wai, J. S., Vacca, J. P., Handt, L., Motzel, S. L., Klein, H. J., Dornadula, G., Danovich, R. M., Witmer, M. V., Wilson, K. A., Tussey, L., Schleif, W. A., Gabryelski, L. S., Jin, L., Miller, M. D., Casimiro, D. R., Emini, E. A., and Shiver, J. W. (2004) Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305, 528-532.
12. Pais, G. C., Zhang, X., Marchand, C., Neamati, N., Cowansage, K., Svarovskaia, E. S., Pathak, V. K., Tang, Y., Nicklaus, M., Pommier, Y., and Burke, T. R., Jr. (2002) Structure Activity of 3-Aryl-1,3-diketo-Containing Compounds as HIV-1 Integrase Inhibitors(1). J. Med. Chem. 45, 3184-3194.
13. Marchand, C., Zhang, X., Pais, G. C., Cowansage, K., Neamati, N., Burke, T. R., Jr, and Pommier, Y. (2002) Structural Determinants for HIV-1 Integrase Inhibition by beta -Diketo Acids. J. Biol. Chem. 277, 12596-12603.
14. Chen, A., Weber, I. T., Harrison, R. W., and Leis, J. (2006) Identification of Amino Acids in HIV-1 and Avian Sarcoma Virus Integrase Subsites Required for Specific Recognition of the Long Terminal Repeat Ends. J. Biol. Chem. 281, 4173-4182.
15. Goldgur, Y., Craigie, R., Cohen, G. H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H., and Davies, D. R. (1999) Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 96, 13040-13043.
16. Dicker, I. B., Samanta, H. K., Li, Z., Hong, Y., Tian, Y., Banville, J., Remillard, R. R., Walker, M. A., Langley, D. R, and Krystal, M. R. (2007) Changes To The HIV LTR And To HIV Integrase Differentially Impact HIV Integrase Assembly, Activity And The Binding Of Strand Transfer Inhibitors. J. Biol. Chem. 282 (43), 31186-31196.
17. De Luca, L., Pedretti, A., Vistoli, G., Letizia Barreca, M., Villa, L., Monforte, P., and Chimirri, A. (2003) Analysis of the full-length integrase-DNA complex by a modified approach for DNA docking. Biochem. Biophys. Res. Commun. 310, 1083-1088.
18. Wang, L. D., Liu, C. L., Chen, W. Z., and Wang, C. X. (2005) Constructing HIV-1 integrase tetramer and exploring influences of metal ions on forming integrase-DNA complex. Biochem. Biophys. Res. Commun. 337, 313-319.
19. Karki, R. G., Tang, Y., Burke, T. R., Jr., and Nicklaus, M. C. (2004) Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J. Comput.-Aided Mol. Des. 18, 739-760.
20. Wielens, J., Crosby, I. T., and Chalmers, D. K. (2005) A three-dimensional model of the human immunodeficiency virus type 1 integration complex. J. Comput.-Aided Mol. Des. 19, 301-317.
21. Gao, K., Butler, S. L., and Bushman, F. (2001) Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. EMBO J. 20, 3565-3576.
22. Bourke, D. G., Chalmers, D. K., Jones, R. D., Crosby, I. T., and Wielens, J. (2001) Molecular modeling of inhibitors in the active site of HIV-1 integrase, presented at the 14th International Conference on Antivirus Research, Seattle, WA, April, 2001.
23. Grobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., Wai, J. S., Young, S., Vacca, J., and Hazuda, D. J. (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 99, 6661-6666.
24. Marchand, C., Johnson, A. A., Karki, R. G., Pais, G. C., Zhang, X., Cowansage, K., Patel, T. A., Nicklaus, M. C, Burke, T. R, Jr., and Pommier, Y. (2003) Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol. 64, 600-609.
25. Maurin, C., Bailly, F., Buisine, E., Vezin, H., Mbemba, G., Mouscadet, J. F., and Cotelle, P. (2004) Spectroscopic Studies of Diketoacids-Metal Interactions. A Probing Tool for the Pharmacophoric Intermetallic Distance in the HIV-1 Integrase Active Site. J. Med. Chem. 47, 5583-5586.
26. Sotriffer, C. A., Ni, H., and McCammon, J. A. (2000) Active site binding modes of HIV-1 integrase inhibitors. J. Med. Chem. 43, 4109-4117.
27. Carlson, H. A., Masukawa, K. M., Rubins, K., Bushman, F. D., Jorgensen, W. L., Lins, R. D., Briggs, J. M., and McCammon, J. A. (2000) Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 43, 2100-2114.
28. Barreca, M. L., DeLuca, L., Iraci, N., and Chimirri, A. (2006) Binding Mode Prediction of Strand Transfer HIV-1 Integrase Inhibitors Using Tn5 Transposase as a Plausible Surrogate Model for HIV-1 Integrase. J. Med. Chem. 49 (13), 3994-3997.
29. Cox, A. G., and Nair, V. (2006) Novel HIV integrase inhibitors with anti-HIV activity: insights into integrase inhibition from docking studies. Antiviral Chem. Chemother. 17, 343-353.
30. Fikkert, V., Van Maele, B., Vercammen, J., Hantson, A., Van Remoortel, B., Michiels, M., Gurnari, C., Pannecouque, C., De Maeyer, M., Engelborghs, Y., De Clercq, E., Debyser, Z., and Witvrouw, M. (2003) Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations. J. Virol. 77, 11459-11470.
31. King, P. J., Lee, D. J., Reinke, R. A., Victoria, J. G., Beale, K., and Robinson, W. E. (2003) Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology 306, 147-161.
32. Fikkert, V., Hombrouck, A., Van Remoortel, B., De Maeyer, M., Pannecouque, C., De Clercq, E., Debyser, Z., and Witvrouw, M. (2004) Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 18, 2019-2020.
33. Hazuda, D. J., Anthony, N. J., Gomez, R. P., Jolly, S. M., Wai, J. S., Zhuang, L., Fisher, T. E., Embrey, M., Guare, J. P, Jr., Egbertson, M. S., Vacca, J. P., Huff, J. R., Felock, P. J., Witmer, M. V., Stillmock, K. A., Danovich, R., Grobler, J., Miller, M. D., Espeseth, A. S., Jin, L., Chen, I. W., Lin, J. H., Kassahun, K., Ellis, J. D., Wong, B. K., Xu, W., Pearson, P. G., Schleif, W. A., Cortese, R., Emini, E., Summa, V., Holloway, M. K., and Young, S. D. (2004) A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. U.S.A. 101, 11233-11238.
34. Herring, B. L., Cunningham, A. L., and Dwyer, D. E. (2004) Potential Drug Resistance Polymorphisms in the Integrase Gene of HIV Type 1 Subtype A. AIDS Res. Hum. Retroviruses 20, 1010-1014.
35. Lee, D. J., and Robinson, W. E., Jr. (2004) Human Immunodeficiency Virus Type 1 (HIV-1) Integrase: Resistance to Diketo Acid Integrase Inhibitors Impairs HIV-1 Replication and Integration and Confers Cross-Resistance to L-Chicoric Acid. J. Virol. 78, 5835-5847.
36. Kehlenbeck, S., Betz, U., Birkmann, A., Fast, B., Goller, A. H., Henninger, K., Lowinger, T., Marrero, D., Paessens, A., Paulsen, D., Pevzner, V., Schohe-Loop, R., Tsujishita, H., Welker, R., Kreuter, J., Rubsamen-Waigmann, H., and Dittmer, F. (2006) Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore. J. Virol. 80, 6883-6894.
37. Lee, D. J., and Robinson, W. E., Jr. (2006) Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors. Antimicrob. Agents Chemother. 50, 134-142.
38. Bevilacqua, P., Kierzek, R., Johnson, K. A., and Turner, D. H. (1992) Dynamics of Ribozyme Binding of Substrate Revealed by Fluorescence-Directed Stopped-Flow Methods. Science 258, 1355-1358.
39. Pandey, K., Bera, S., Zahm, J., Vora, A., Stillmock, K., Hazuda, D., and Grandgenett, D. (2007) Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J. Virol. 81, 12189-12199.
40. Jenkins, T. M., Esposito, D., Engelman, A., and Craigie, R. (1997) Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J. 16, 6849-6859.
41. Goldhaber-Gordon, I., Early, M. H., and Baker, T. A. (2003) The terminal nucleotide of the Mu genome controls catalysis of DNA strand transfer. Proc. Natl. Acad. Sci. U.S.A. 100, 7509-7514.
42. Chen, X., Tsiang, M., Yu, F., Hung, M., Jones, G. S., Zeynalzadegan, A., Qi, X, Jin, H., Kim, C. U., Swaminathan, S., and Chen, J. M. (2008) Modeling, Analysis, and Validation of a Novel HIV Integrase Structure Provide Insights into the Binding Modes of Potent Integrase Inhibitors. J. Mol. Biol. 380, 504-519.
43. Alderton, W. K., Boyhan, A., and Lowe, P. N. (1998) Nitroarginine and tetrahydrobiopterin binding to the haem domain of neuronal nitric oxide synthase using a scintillation proximity assay. Biochem. J. 332, 195-201.
44. Furfine, E. S., Harmon, M. F., and Paith, J. E. (1993) Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine. Biochemistry 32, 8512-8517.
45. Gorren, A. C. F., Schrammel, A., Schmidt, K., and Mayer, B. 1998Effects of pH on the structure and function of neuronal nitric oxide synthaseBiochem. J. 331, 801-807.
46. Langmead, C. J., Jerman, J. C., Brough, S. J., Scott, C., Porter, R. A., and Herdon, H. J. (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br. J. Pharmacol. 141, 340-346.
47. North, A. M. (1964)The Collision Theory of Chemical Reactions in Liquids, pp 258-259, Methuen, London.